CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Pfizer INC (PFE) / ritlecitinib
Forward catalyst · PFE

ritlecitinib

Sponsor Pfizer INC · listed as PFE

READOUT Phase 3 Confidence: medium Source: clinicaltrials

ritlecitinib is a clinical-stage drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Dec 21, 2026 (day precision, medium confidence), tied to trial NCT06873945. The asset is in Phase 3 and currently active not recruiting, studied in Alopecia Areata. It appears across 3 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-12-21
As disclosedDec 21, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06873945
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorPfizer
Listed asPFE
Condition(s)Alopecia Areata

All tracked catalysts for ritlecitinib

DateEventConfidenceTrial
2026-12-21READOUTmediumNCT06873945
2027-03-31READOUTmediumNCT06163326
2027-07-30READOUTmediumNCT06072183
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More PFE catalysts